<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529577</url>
  </required_header>
  <id_info>
    <org_study_id>HIS-PrEF_study</org_study_id>
    <nct_id>NCT04529577</nct_id>
  </id_info>
  <brief_title>His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection Fraction</brief_title>
  <acronym>HIS-PrEF</acronym>
  <official_title>His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares standard right ventricle apical pacing with so called His-bundle pacing,&#xD;
      for patients with slightly or moderately reduced ejection fraction and atrioventricular block&#xD;
      requiring pacemaker therapy. The primary outcome is left ventricular ejection fraction&#xD;
      measured after 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with reduced systolic ejection fraction (40≤ ejection fraction ≤55%) and pacemaker&#xD;
      indication due to high degree AV block are included. The study has a randomized double&#xD;
      blinded crossover design. Patients are implanted with a standard right ventricle lead and&#xD;
      right atrial lead (if indicated), and in addition a His-bundle lead. Randomization is&#xD;
      performed as to which pacing modality is used during the first 6 months. After 6 months the&#xD;
      pacing modality is changed. Patients are blinded and endpoint adjudicators, including&#xD;
      echocardiography staff, are blinded. Device nurse and physician are not blinded.&#xD;
&#xD;
      Primary endpoint is difference in left ventricular ejection fraction after 6 months, paired&#xD;
      comparisons are used and each patient is their own control. Secondary endpoints include&#xD;
      complications and safety of the device/electrode, and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized double blinded crossover design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Patients and outcomes assessors are blinded. Staff involved in device programming are not blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ejection Fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute difference in left ventricular systolic ejection fraction (absolute percent)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of device-related adverse events. Events will be classified as general, associated with His-bundle lead or associated with RV lead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular activation time</measure>
    <time_frame>6 months</time_frame>
    <description>Total left ventricular mechanical activation time (measured with tissue doppler echocardiography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-ProBNP</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in NT-ProBNP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS duration</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in total QRS duration on ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Activation Time (LVAT)</measure>
    <time_frame>6 months</time_frame>
    <description>Maximum unipolar spike-to-peak-T-wave in V5-V6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in six minute hall walk test (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life measured by the Short Form Health Survey (SF-36) mean score</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in health related quality of life, measured by the SF-36 questionnaire, calculated as difference in mean from baseline to follow-up (calculated using the official scoring algorithm, where each sub scale is assigned a score between 0-100, higher score represents better health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life measured by the EuroQol EQ-5D-5L Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in health related quality of life, measured by the mean score of the EQ-5D (version 5L) questionnaire (totalt score ranging from 5-25 points, higher score represents more health related problems/disability)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>His Bundle Pacing</condition>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>His-bundle pacing first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV apical pacing first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>His-bundle pacing</intervention_name>
    <description>A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).&#xD;
A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup.</description>
    <arm_group_label>His-bundle pacing first</arm_group_label>
    <arm_group_label>RV apical pacing first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AV block II or III with high expected pacing need&#xD;
&#xD;
          -  Left ventricular ejection fraction between 40% and 55% (inclusive)&#xD;
&#xD;
          -  Willing to participate and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years old&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Cardiac sarcoidosis&#xD;
&#xD;
          -  Cardiac amyloidosis&#xD;
&#xD;
          -  Previous myocardial infarction within last 3 months&#xD;
&#xD;
          -  Ventricular septum defect or other other left ventricular corrective surgery&#xD;
&#xD;
          -  Congenital heart disease surgically corrected&#xD;
&#xD;
          -  Atrial fibrillation with uncontrolled rate (if not planned for AV node ablation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Borgquist, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University, Skane University Hospital, Arrhythmia Section, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maiwand Farouq, MD, PhD</last_name>
    <phone>+ 46 40 336415‬</phone>
    <email>maiwand.farouq@skane.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rasmus Borgquist, MD</last_name>
    <phone>+46 46 171010</phone>
    <email>rasmus.borgquist@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasmus Borgquist</last_name>
      <phone>+4646171000</phone>
      <email>rasmus.borgquist@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steen Jensen, MD PhD</last_name>
      <email>steen.jensen@medicin.umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Region Hallands Sjukhus Varberg</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Rorsman</last_name>
      <email>Cecilia.Rorsman@regionhalland.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>His bundle pacing</keyword>
  <keyword>Conduction system pacing</keyword>
  <keyword>Heart failure, systolic</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Left ventricular ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

